A randomized Phase 3 cogitation by...

A randomized Phase 3 cogitation by Genentech, Inc. (South San Francisco, CA) and Xoma Ltd Berkeley, CA), with Raptiva (efalizumab), a therapy for moderate-to-severe psoriasis, achieved its primary endpoint, comparing the percentage of enthralls who achieved 75% or greater improvement in psoriasis area and severity index (PASI) scores after 12 weeks of contemplation drug therapy with subjects receiving placebo. The double-blind,